{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:44:38Z","timestamp":1793727878395,"version":"4.6.1"},"reference-count":58,"publisher":"Harborside Press, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel\u2019s discussions on select 2026 updates to the guidelines regarding nonmetastatic disease: the elimination of the very-low-risk group, updates to the Principles of Active Surveillance, and caution in the use of focal therapy in newly diagnosed patients.<\/jats:p>","DOI":"10.6004\/jnccn.2026.0023","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:32:13Z","timestamp":1778754733000},"page":"140-149","source":"Crossref","is-referenced-by-count":14,"title":["NCCN Guidelines\u00ae Insights: Prostate Cancer, Version 5.2026"],"prefix":"10.6004","volume":"24","author":[{"given":"Daniel E.","family":"Spratt","sequence":"first","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Srinivas","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Adra","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilawal","family":"Ahmed","sequence":"additional","affiliation":[{"name":"The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"An","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"Bitting","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Chapin","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather H.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve Y.","family":"Cho","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Victor","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center | Mass General Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Desai","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Dorff","sequence":"additional","affiliation":[{"name":"City of Hope National Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Eastham","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Farrington","sequence":"additional","affiliation":[{"name":"Prostate Health Education Network (PHEN)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center | Mass General Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Ippolito","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Jeffrey","family":"Karnes","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Kuettel","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Lang","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lee","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at The University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Lotan","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McDonald","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Morgan","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Pessoa","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soroush","family":"Rais-Bahrami","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mack","family":"Roach","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Robin","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"University of California San Francisco Patient Services Committee Chair"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen R.","family":"Scarpato","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Seibert","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Shabsigh","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Szmulewitz","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Teply","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Tward","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Valicenti","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"VanderWeele","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Karen","family":"Wong","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Kovach","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Freedman-Cass","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel RL","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS,  Cancer statistics, 2026. CA Cancer J Clin 2026;76:e70043."},{"key":"B2","series-title":"Oncology (Williston Park)","first-page":"111","article-title":"NCCN Practice Guidelines for Prostate Cancer","volume":"14","author":"Bahnson RR","year":"2000","unstructured":"Bahnson RR, Hanks GE, Huben RP,  NCCN Practice Guidelines for Prostate Cancer. Oncology (Williston Park) 2000;14:111\u2013119."},{"key":"B3","series-title":"Cancer","first-page":"281","article-title":"Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era","volume":"95","author":"D\u2019Amico AV","year":"2002","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB,  Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002;95:281\u2013286."},{"key":"B4","series-title":"JAMA","first-page":"969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico AV","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB,  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969\u2013974."},{"key":"B5","series-title":"Brachytherapy","first-page":"43","article-title":"Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy","volume":"19","author":"Tom MC","year":"2020","unstructured":"Tom MC, Reddy CA, Smile TD,  Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy. Brachytherapy 2020;19:43\u201350."},{"key":"B6","series-title":"J Urol","first-page":"284","article-title":"International multicenter validation of an intermediate risk subclassification of prostate cancer managed with radical treatment without hormone therapy","volume":"201","author":"Berlin A","year":"2019","unstructured":"Berlin A, Moraes FY, Sanmamed N,  International multicenter validation of an intermediate risk subclassification of prostate cancer managed with radical treatment without hormone therapy. J Urol 2019;201:284\u2013291."},{"key":"B7","series-title":"J Urol","first-page":"354","article-title":"Oncologic and functional outcomes after radical prostatectomy for high or very high risk prostate cancer: European validation of the current NCCN\u00ae guideline","volume":"198","author":"Pompe RS","year":"2017","unstructured":"Pompe RS, Karakiewicz PI, Tian Z,  Oncologic and functional outcomes after radical prostatectomy for high or very high risk prostate cancer: European validation of the current NCCN\u00ae guideline. J Urol 2017;198:354\u2013361."},{"key":"B8","series-title":"Asian J Androl","first-page":"551","article-title":"National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients","volume":"20","author":"Xu H","year":"2018","unstructured":"Xu H, Zhu Y, Dai B, Ye DW. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients. Asian J Androl 2018;20:551\u2013554."},{"key":"B9","series-title":"JAMA","first-page":"368","article-title":"Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer","volume":"271","author":"Epstein JI","year":"1994","unstructured":"Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368\u2013374."},{"key":"B10","series-title":"J Urol","first-page":"10","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham JA","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA,  Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management. J Urol 2022;208:10\u201318."},{"key":"B11","series-title":"JAMA Oncol","first-page":"e203187","article-title":"Tailoring intensity of active surveillance for low-risk prostate cancer based on individualized prediction of risk stability","volume":"6","author":"Cooperberg MR","year":"2020","unstructured":"Cooperberg MR, Zheng Y, Faino AV,  Tailoring intensity of active surveillance for low-risk prostate cancer based on individualized prediction of risk stability. JAMA Oncol 2020;6:e203187."},{"key":"B12","series-title":"Eur Urol","first-page":"713","article-title":"Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the prostate cancer intervention versus observation trial (PIVOT)","volume":"77","author":"Wilt TJ","year":"2020","unstructured":"Wilt TJ, Vo TN, Langsetmo L,  Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the prostate cancer intervention versus observation trial (PIVOT). Eur Urol 2020;77:713\u2013724."},{"key":"B13","series-title":"Eur Urol","first-page":"547","article-title":"Primary whole-gland ablation for the treatment of clinically localized prostate cancer: a Focal Therapy Society best practice statement","volume":"84","author":"Deivasigamani S","year":"2023","unstructured":"Deivasigamani S, Kotamarti S, Rastinehad AR,  Primary whole-gland ablation for the treatment of clinically localized prostate cancer: a Focal Therapy Society best practice statement. Eur Urol 2023;84:547\u2013560."},{"key":"B14","series-title":"Cancer","first-page":"323","article-title":"A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer","volume":"116","author":"Donnelly BJ","year":"2010","unstructured":"Donnelly BJ, Saliken JC, Brasher PM,  A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010;116:323\u2013330."},{"key":"B15","series-title":"Cancer","first-page":"4695","article-title":"A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes","volume":"115","author":"Robinson JW","year":"2009","unstructured":"Robinson JW, Donnelly BJ, Siever JE,  A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer 2009;115:4695\u20134704."},{"key":"B16","series-title":"J Urol","first-page":"1170","article-title":"Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b)","volume":"188","author":"Chin JL","year":"2012","unstructured":"Chin JL, Al-Zahrani AA, Autran-Gomez AM,  Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b). J Urol 2012;188:1170\u20131175."},{"key":"B17","series-title":"J Urol","first-page":"769","article-title":"Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate cancer","volume":"205","author":"Klotz L","year":"2021","unstructured":"Klotz L, Pavlovich CP, Chin J,  Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate cancer. J Urol 2021;205:769\u2013779."},{"key":"B18","series-title":"Eur Urol","first-page":"526","article-title":"Whole-gland or subtotal high-intensity focused ultrasound versus radical prostatectomy: the prospective, noninferiority, nonrandomized HIFI trial","volume":"87","author":"Ploussard G","year":"2025","unstructured":"Ploussard G, Coloby P, Chevallier T,  Whole-gland or subtotal high-intensity focused ultrasound versus radical prostatectomy: the prospective, noninferiority, nonrandomized HIFI trial. Eur Urol 2025;87:526\u2013533."},{"key":"B19","series-title":"Lancet Oncol","first-page":"181","article-title":"Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial","volume":"18","author":"Azzouzi AR","year":"2017","unstructured":"Azzouzi AR, Vincendeau S, Barret E,  Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol 2017;18:181\u2013191."},{"key":"B20","series-title":"Lancet Oncol","first-page":"910","article-title":"MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study","volume":"23","author":"Ehdaie B","year":"2022","unstructured":"Ehdaie B, Tempany CM, Holland F,  MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study. Lancet Oncol 2022;23:910\u2013918."},{"key":"B21","series-title":"World J Urol","first-page":"1293","article-title":"Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected","volume":"41","author":"Duwe G","year":"2023","unstructured":"Duwe G, Boehm K, Haack M,  Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected. World J Urol 2023;41:1293\u20131299."},{"key":"B22","series-title":"J Urol","first-page":"983","article-title":"Prospective multicenter phase II study on focal therapy (hemiablation) of the prostate with high intensity focused ultrasound","volume":"199","author":"Ganzer R","year":"2018","unstructured":"Ganzer R, Hadaschik B, Pahernik S,  Prospective multicenter phase II study on focal therapy (hemiablation) of the prostate with high intensity focused ultrasound. J Urol 2018;199:983\u2013989."},{"key":"B23","series-title":"Radiology","first-page":"e231473","article-title":"MRI-guided focused ultrasound focal therapy for intermediate-risk prostate cancer: final results from a 2-year phase II clinical trial","volume":"310","author":"Ghai S","year":"2024","unstructured":"Ghai S, Finelli A, Corr K,  MRI-guided focused ultrasound focal therapy for intermediate-risk prostate cancer: final results from a 2-year phase II clinical trial. Radiology 2024;310:e231473."},{"key":"B24","series-title":"J Urol","first-page":"1670","article-title":"Phase II evaluation of magnetic resonance imaging guided focal laser ablation of prostate cancer","volume":"196","author":"Eggener SE","year":"2016","unstructured":"Eggener SE, Yousuf A, Watson S,  Phase II evaluation of magnetic resonance imaging guided focal laser ablation of prostate cancer. J Urol 2016;196:1670\u20131675."},{"key":"B25","series-title":"J Urol","first-page":"e714","article-title":"PD19-01: Final, three-year oncological results of a randomized clinical trial FARP comparing focal ablation and radical prostatectomy in patients with unilateral clinically significant prostate cancer","volume":"213","author":"Baco E","year":"2025","unstructured":"Baco E, Noor D, Galtung KF, Rud E. PD19-01: Final, three-year oncological results of a randomized clinical trial FARP comparing focal ablation and radical prostatectomy in patients with unilateral clinically significant prostate cancer. J Urol 2025;213(Suppl 5):e714."},{"key":"B26","series-title":"Prostate Cancer Prostatic Dis","first-page":"693","article-title":"Established focal therapy-HIFU, IRE, or cryotherapy-where are we now? A systematic review and meta-analysis","volume":"28","author":"Tay KJ","year":"2025","unstructured":"Tay KJ, Fong KY, Stabile A,  Established focal therapy-HIFU, IRE, or cryotherapy-where are we now? A systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2025;28:693\u2013706."},{"key":"B27","series-title":"Eur Urol","first-page":"5","article-title":"An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years?","volume":"81","author":"Hopstaken JS","year":"2022","unstructured":"Hopstaken JS, Bomers JGR, Sedelaar MJP,  An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years? Eur Urol 2022;81:5\u201333."},{"key":"B28","series-title":"World J Urol","first-page":"1309","article-title":"Contemporary patterns of local ablative therapies for prostate cancer at United States cancer centers: results from a national registry","volume":"41","author":"Koelker M","year":"2023","unstructured":"Koelker M, Labban M, Frego N,  Contemporary patterns of local ablative therapies for prostate cancer at United States cancer centers: results from a national registry. World J Urol 2023;41:1309\u20131315."},{"key":"B29","series-title":"J Urol","first-page":"e626","article-title":"National patterns of focal therapy use among patients with prostate cancer [abstract]","volume":"213","author":"Smani S","year":"2025","unstructured":"Smani S, Lokeshwar SD, Palencia PS,  National patterns of focal therapy use among patients with prostate cancer [abstract]. J Urol 2025;213(Suppl 5):e626."},{"key":"B1","series-title":"CA Cancer J Clin","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel RL","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS,  Cancer statistics, 2026. CA Cancer J Clin 2026;76:e70043."},{"key":"B2","series-title":"Oncology (Williston Park)","first-page":"111","article-title":"NCCN Practice Guidelines for Prostate Cancer","volume":"14","author":"Bahnson RR","year":"2000","unstructured":"Bahnson RR, Hanks GE, Huben RP,  NCCN Practice Guidelines for Prostate Cancer. Oncology (Williston Park) 2000;14:111\u2013119."},{"key":"B3","series-title":"Cancer","first-page":"281","article-title":"Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era","volume":"95","author":"D\u2019Amico AV","year":"2002","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB,  Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002;95:281\u2013286."},{"key":"B4","series-title":"JAMA","first-page":"969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico AV","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB,  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969\u2013974."},{"key":"B5","series-title":"Brachytherapy","first-page":"43","article-title":"Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy","volume":"19","author":"Tom MC","year":"2020","unstructured":"Tom MC, Reddy CA, Smile TD,  Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy. Brachytherapy 2020;19:43\u201350."},{"key":"B6","series-title":"J Urol","first-page":"284","article-title":"International multicenter validation of an intermediate risk subclassification of prostate cancer managed with radical treatment without hormone therapy","volume":"201","author":"Berlin A","year":"2019","unstructured":"Berlin A, Moraes FY, Sanmamed N,  International multicenter validation of an intermediate risk subclassification of prostate cancer managed with radical treatment without hormone therapy. J Urol 2019;201:284\u2013291."},{"key":"B7","series-title":"J Urol","first-page":"354","article-title":"Oncologic and functional outcomes after radical prostatectomy for high or very high risk prostate cancer: European validation of the current NCCN\u00ae guideline","volume":"198","author":"Pompe RS","year":"2017","unstructured":"Pompe RS, Karakiewicz PI, Tian Z,  Oncologic and functional outcomes after radical prostatectomy for high or very high risk prostate cancer: European validation of the current NCCN\u00ae guideline. J Urol 2017;198:354\u2013361."},{"key":"B8","series-title":"Asian J Androl","first-page":"551","article-title":"National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients","volume":"20","author":"Xu H","year":"2018","unstructured":"Xu H, Zhu Y, Dai B, Ye DW. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients. Asian J Androl 2018;20:551\u2013554."},{"key":"B9","series-title":"JAMA","first-page":"368","article-title":"Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer","volume":"271","author":"Epstein JI","year":"1994","unstructured":"Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368\u2013374."},{"key":"B10","series-title":"J Urol","first-page":"10","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham JA","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA,  Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management. J Urol 2022;208:10\u201318."},{"key":"B11","series-title":"JAMA Oncol","first-page":"e203187","article-title":"Tailoring intensity of active surveillance for low-risk prostate cancer based on individualized prediction of risk stability","volume":"6","author":"Cooperberg MR","year":"2020","unstructured":"Cooperberg MR, Zheng Y, Faino AV,  Tailoring intensity of active surveillance for low-risk prostate cancer based on individualized prediction of risk stability. JAMA Oncol 2020;6:e203187."},{"key":"B12","series-title":"Eur Urol","first-page":"713","article-title":"Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the prostate cancer intervention versus observation trial (PIVOT)","volume":"77","author":"Wilt TJ","year":"2020","unstructured":"Wilt TJ, Vo TN, Langsetmo L,  Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the prostate cancer intervention versus observation trial (PIVOT). Eur Urol 2020;77:713\u2013724."},{"key":"B13","series-title":"Eur Urol","first-page":"547","article-title":"Primary whole-gland ablation for the treatment of clinically localized prostate cancer: a Focal Therapy Society best practice statement","volume":"84","author":"Deivasigamani S","year":"2023","unstructured":"Deivasigamani S, Kotamarti S, Rastinehad AR,  Primary whole-gland ablation for the treatment of clinically localized prostate cancer: a Focal Therapy Society best practice statement. Eur Urol 2023;84:547\u2013560."},{"key":"B14","series-title":"Cancer","first-page":"323","article-title":"A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer","volume":"116","author":"Donnelly BJ","year":"2010","unstructured":"Donnelly BJ, Saliken JC, Brasher PM,  A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010;116:323\u2013330."},{"key":"B15","series-title":"Cancer","first-page":"4695","article-title":"A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes","volume":"115","author":"Robinson JW","year":"2009","unstructured":"Robinson JW, Donnelly BJ, Siever JE,  A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer 2009;115:4695\u20134704."},{"key":"B16","series-title":"J Urol","first-page":"1170","article-title":"Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b)","volume":"188","author":"Chin JL","year":"2012","unstructured":"Chin JL, Al-Zahrani AA, Autran-Gomez AM,  Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b). J Urol 2012;188:1170\u20131175."},{"key":"B17","series-title":"J Urol","first-page":"769","article-title":"Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate cancer","volume":"205","author":"Klotz L","year":"2021","unstructured":"Klotz L, Pavlovich CP, Chin J,  Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate cancer. J Urol 2021;205:769\u2013779."},{"key":"B18","series-title":"Eur Urol","first-page":"526","article-title":"Whole-gland or subtotal high-intensity focused ultrasound versus radical prostatectomy: the prospective, noninferiority, nonrandomized HIFI trial","volume":"87","author":"Ploussard G","year":"2025","unstructured":"Ploussard G, Coloby P, Chevallier T,  Whole-gland or subtotal high-intensity focused ultrasound versus radical prostatectomy: the prospective, noninferiority, nonrandomized HIFI trial. Eur Urol 2025;87:526\u2013533."},{"key":"B19","series-title":"Lancet Oncol","first-page":"181","article-title":"Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial","volume":"18","author":"Azzouzi AR","year":"2017","unstructured":"Azzouzi AR, Vincendeau S, Barret E,  Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol 2017;18:181\u2013191."},{"key":"B20","series-title":"Lancet Oncol","first-page":"910","article-title":"MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study","volume":"23","author":"Ehdaie B","year":"2022","unstructured":"Ehdaie B, Tempany CM, Holland F,  MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study. Lancet Oncol 2022;23:910\u2013918."},{"key":"B21","series-title":"World J Urol","first-page":"1293","article-title":"Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected","volume":"41","author":"Duwe G","year":"2023","unstructured":"Duwe G, Boehm K, Haack M,  Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected. World J Urol 2023;41:1293\u20131299."},{"key":"B22","series-title":"J Urol","first-page":"983","article-title":"Prospective multicenter phase II study on focal therapy (hemiablation) of the prostate with high intensity focused ultrasound","volume":"199","author":"Ganzer R","year":"2018","unstructured":"Ganzer R, Hadaschik B, Pahernik S,  Prospective multicenter phase II study on focal therapy (hemiablation) of the prostate with high intensity focused ultrasound. J Urol 2018;199:983\u2013989."},{"key":"B23","series-title":"Radiology","first-page":"e231473","article-title":"MRI-guided focused ultrasound focal therapy for intermediate-risk prostate cancer: final results from a 2-year phase II clinical trial","volume":"310","author":"Ghai S","year":"2024","unstructured":"Ghai S, Finelli A, Corr K,  MRI-guided focused ultrasound focal therapy for intermediate-risk prostate cancer: final results from a 2-year phase II clinical trial. Radiology 2024;310:e231473."},{"key":"B24","series-title":"J Urol","first-page":"1670","article-title":"Phase II evaluation of magnetic resonance imaging guided focal laser ablation of prostate cancer","volume":"196","author":"Eggener SE","year":"2016","unstructured":"Eggener SE, Yousuf A, Watson S,  Phase II evaluation of magnetic resonance imaging guided focal laser ablation of prostate cancer. J Urol 2016;196:1670\u20131675."},{"key":"B25","series-title":"J Urol","first-page":"e714","article-title":"PD19-01: Final, three-year oncological results of a randomized clinical trial FARP comparing focal ablation and radical prostatectomy in patients with unilateral clinically significant prostate cancer","volume":"213","author":"Baco E","year":"2025","unstructured":"Baco E, Noor D, Galtung KF, Rud E. PD19-01: Final, three-year oncological results of a randomized clinical trial FARP comparing focal ablation and radical prostatectomy in patients with unilateral clinically significant prostate cancer. J Urol 2025;213(Suppl 5):e714."},{"key":"B26","series-title":"Prostate Cancer Prostatic Dis","first-page":"693","article-title":"Established focal therapy-HIFU, IRE, or cryotherapy-where are we now? A systematic review and meta-analysis","volume":"28","author":"Tay KJ","year":"2025","unstructured":"Tay KJ, Fong KY, Stabile A,  Established focal therapy-HIFU, IRE, or cryotherapy-where are we now? A systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2025;28:693\u2013706."},{"key":"B27","series-title":"Eur Urol","first-page":"5","article-title":"An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years?","volume":"81","author":"Hopstaken JS","year":"2022","unstructured":"Hopstaken JS, Bomers JGR, Sedelaar MJP,  An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years? Eur Urol 2022;81:5\u201333."},{"key":"B28","series-title":"World J Urol","first-page":"1309","article-title":"Contemporary patterns of local ablative therapies for prostate cancer at United States cancer centers: results from a national registry","volume":"41","author":"Koelker M","year":"2023","unstructured":"Koelker M, Labban M, Frego N,  Contemporary patterns of local ablative therapies for prostate cancer at United States cancer centers: results from a national registry. World J Urol 2023;41:1309\u20131315."},{"key":"B29","series-title":"J Urol","first-page":"e626","article-title":"National patterns of focal therapy use among patients with prostate cancer [abstract]","volume":"213","author":"Smani S","year":"2025","unstructured":"Smani S, Lokeshwar SD, Palencia PS,  National patterns of focal therapy use among patients with prostate cancer [abstract]. J Urol 2025;213(Suppl 5):e626."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/5\/article-p140.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/5\/article-p140.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/5\/article-p140.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:32:15Z","timestamp":1778754735000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/5\/article-p140.xml"}},"subtitle":["Featured Updates to the NCCN Guidelines"],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":58,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.0023","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}